ProCE Banner Activity

Expert Perspectives on the Evolving Treatment of EGFR-Mutated Advanced and Metastatic NSCLC

Slideset

Slides from a 2024 live ASCO satellite symposium covering the recent developments in the rapidly evolving landscape of EGFR-mutant NSCLC, including the use of biomarkers for selecting primary therapy, clinical trial, and expert considerations on the latest practice changing results presented at the ASCO annual meeting.

Released: May 29, 2024

Expiration: May 28, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Boehringer Ingelheim Pharmaceuticals, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC